MagistrlarAnnotatsiya
Metabolism-related fatty liver disease (MAFLD) is a highly prevalent condition strongly
associated with insulin resistance and metabolic syndrome. Liver fibrosis is the most
important prognostic factor determining disease progression and long-term outcomes. The
triglyceride–glucose (TyG) index is a simple and cost-effective surrogate marker of insulin
resistance. Recent evidence suggests that the TyG index may be associated with liver
fibrosis severity in MAFLD patients. This study aimed to evaluate the relationship between
TyG index and liver fibrosis stages in adults with MAFLD using biochemical markers and
noninvasive elastography.
Kalit so'zlar:
TyG index, MAFLD, liver fibrosis, insulin resistance, elastography, metabolic syndrome
Foydalanilgan adabiyotlar
1. Simental-Mendía LE et al. Triglyceride-glucose index as surrogate of insulin resistance. J Clin Endocrinol Metab. 2018. 2. Eslam M et al. MAFLD definition and clinical implications. J Hepatol. 2020. 3. Loomba R, Adams LA. Advances in NAFLD fibrosis assessment. Nat Rev Gastroenterol Hepatol. 2021. 4. Wang J et al. Diagnostic value of TyG index in fatty liver disease. Nutrients. 2022. 5. Zhang S et al. TyG index and NAFLD risk: meta-analysis. Front Endocrinol. 2022. 6. Lee SB et al. TyG index and liver fibrosis association. Clin Gastroenterol Hepatol. 2021. 7. European Association for the Study of the Liver (EASL). Clinical Practice Guidelines. 2021. 8. American Association for the Study of Liver Diseases (AASLD). Practice Guidance. 2022–2023.
